Clinical trials: Patency Rate
Hyperglycemia, Postoperative Infection
Hyperglycemia in Neurosurgery
Poor glycemic control is recognized as a risk factor for postoperative infection. For the neurosurgical patient, postoperative infection can lead to devastating complications such as meningitis, encephalitis and death.
- Trial name
- NCT05236751
- Where
- 3 sites in United States, Italy and 1 more
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center
Coronary Heart Disease
Arachidonic Acid-induced Platelet Aggregation Rate in Patients With Stable CAD Treated With Ticagrelor Monotherapy
This study was a feasibility trial that was designed to provide preliminary observations and generate hypotheses for future studies.
- Trial name
- NCT02219412
- Testing
- ticagrelor, Aspirin
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Yong Huo
Ovarian Neoplasms
A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)
The aim of this study is to evaluate efficacy and tolerability, and number of positive response to treatment with CAELYX (50 mg/m^2), administered as monotherapy once per 4 weeks to patients with metastatic epithelial ovarian…
- Trial name
- NCT00727961
- Testing
- Pegylated Liposomal Doxorubicin hydrochloride
- Volunteers
- 58 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Disease, Chronic Obstructive
Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study to compare the lung and oropharyngeal deposition of Berodual® (fenoterol hydrobromide 50μg + ipratropium bromide 20μg /1x puff) delivered via the Respimat® inhaler and the same dose of Berodual® delivered via an…
- Trial name
- NCT02176200
- Testing
- Berodual® Respimat®, low inspiratory flow rate, Berodual® Respimat®, medium inspiratory flow rate, Berodual® Respimat®, high inspiratory flow rate
- Volunteers
- 3 people
- Sponsor
- Boehringer Ingelheim
Epidural; Anesthesia
Does Ultrasound Increase the First-pass Success of Epidural Space Identification in Obese Parturients
Obesity is associated with difficulties in epidural space catheterization. The investigators want to prove that a pre-procedural ultrasound exam of lumbar spine increase the first-pass success rate of the epidural space…
- Trial name
- NCT04352283
- Testing
- Preprocedural ultrasound exam of lumbar spine
- Where
- France
- Volunteers
- 56 people
- Sponsor
- University Hospital, Caen
Healthy Volunteers
A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants
The objective of this study is to evaluate the bioavailability, safety and tolerability of risankizumab following subcutaneous injections in healthy male participants.
- Trial name
- NCT05283694
- Testing
- risankizumab
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AbbVie
Persistent or Chronic ITP
Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in ITP
Thrombopoietin-receptor agonists (Tpo-RAs) have profoundly changed the management of ITP. However, today, there are no international recommendations concerning the long-term use of these costly, potentially pro-thrombotic agents…
- Trial name
- STOP-AGO (NCT03119974)
- Testing
- Tpo-RA discontinuation
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Colorectal Cancer
A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer
This single arm study will assess the efficacy and safety of treatment with Xeloda plus standard pelvic radiotherapy in participants with locally advanced rectal cancer.
- Trial name
- NCT00796718
- Testing
- Standard radiotherapy, Capecitabine [Xeloda]
- Where
- 2 sites in Slovakia
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
Neurosurgery, Cardiovascular System
Fluid Challenge Infusion and Response
It is unclear if the rate of administration of the fluid challenge could affect the rate of fluid responsiveness. The role of this small-dose (the so called mini-FC) has been recently tested to assess if the infusion of a small…
- Conditions
- Neurosurgery, Cardiovascular System, Anesthesia, General
- Trial name
- REFILL (NCT03810118)
- Testing
- fluid challenge
- Where
- Italy
- Volunteers
- 49 people
- Sponsor
- Humanitas Clinical and Research Center
Colon Cancer
Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）
The goal of this clinical trial is to evaluate the efficacy and safety of conversion therapy using radiotherapy combined with systemic treatment (chemotherapy + immune checkpoint inhibitors) for patients with pMMR/MSS T4M0 stage…
- Trial name
- NCT06949111
- Testing
- radiotherapy, CAPOX, Capecitabine
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Hebei Medical University Fourth Hospital
Progression-free Survival, Overall Survival
Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma
After standard multimodal therapy, the prognosis of relapsed and unresectable high-grade osteosarcoma is dismal and unchanged over the last decades.
- Conditions
- Progression-free Survival, Overall Survival, Clinical Benefit Rate, Toxicity
- Trial name
- APFAO (NCT03359018)
- Testing
- Apatinib, SHR-1210
- Where
- 2 sites in China
- Volunteers
- 43 people
- Sponsor
- Peking University People's Hospital
Patients With Schizophrenia
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia
Schizophrenia is a severe chronic mental disorder with a long-term treatment. Most antipsychotic (AP) drugs are effective for only 30% to 60% of patients and for many drugs, treatment selection remains a "trial-and-error"…
- Trial name
- PROMISE (NCT05839613)
- Testing
- Therapeutic Drug Monitoring (TDM) and Pharmacogenetics (PG)
- Volunteers
- 400 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
HIV Infections
New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients
This is a multi-center, open-label, non-randomized proof-of-concept trial. Two cooperating HIV-specialized centres represented by Dr. med. Hans Jaeger and Prof. Dr.
- Trial name
- NewEra (NCT00908544)
- Testing
- PHI-patients, CHI-patients
- Where
- 8 sites in Germany
- Volunteers
- 47 people
- Sponsor
- MUC Research GmbH
Colorectal Cancer
A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer.
This open-label study will assess the efficacy and safety of Avastin (bevacizumab) plus Xeloda (capecitabine) in combination with standard technique radiotherapy of the pelvic region in the neo-adjuvant setting in patients with…
- Trial name
- NCT01227707
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda], Radiation therapy
- Where
- 9 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Vital Sign Evaluation
A Multi-Center Prospective Open Label Study of a Web-based Application for Pulse Rate in Adult Patients
Evaluating the Accuracy of a Web-Based Application - Vital Sign Measurement Platform Description This single-arm cohort, open-label, and multi-center study is designed to evaluate the accuracy of a web-based application designed…
- Trial name
- NCT05853380
- Testing
- Informed Vital Core App
- Where
- 6 sites in United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Mindset Medical
POSEIDON Category 4, Low Prognosis in Assisted Reproductive Technology
Impact of Day 2 Versus Day 3 Fresh Embryo Transfer on Live Birth Rate in Poor-Prognosis Patients
This study aimed to compare the efficacy (live birth rate) of fresh embryo transfer on Day 2 versus Day 3 in POSEIDON Group 4 patients, and to determine the optimal timing of embryo transfer for this population.
- Conditions
- POSEIDON Category 4, Low Prognosis in Assisted Reproductive Technology, Female Infertility Due to Diminished Ovarian Reserve
- Trial name
- NCT07533695
- Testing
- Day 2 Fresh Embryo Transfer
- Volunteers
- 470 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Chronic Myeloid Leukemia
An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years
This is an open-label, multicenter, randomised phase 3b clinical trial of Imatinib 400 to 800 mg daily versus Nilotinib 300 mg two times daily in chronic phase CML patients with confirmed MMR without MR4.5
- Trial name
- DECLINE (NCT02174445)
- Testing
- Imatinib, Nilotinib
- Where
- 18 sites in Germany
- Volunteers
- 14 people
- Sponsor
- Prof. Dr. Nikolas von Bubnoff
Side Effect of Drug
Evaluation of Safety, Rate and Extent of Absorption of Psilocin Mucate
Psilocin is the active metabolite of psilocybin a natural material found in several types of fungi. The bioavailability of psilocybin, the prodrug of psilocin, has been reported to be over 60%.
- Trial name
- Psilocin-1 (NCT06035900)
- Testing
- Psilocin
- Where
- Jordan
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Lobe Sciences Ltd.
Parkinson's Disease, Motor Symptoms
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
This study is designed to assess the effect of APOKYN treatment in rapid and reliable improvement of motor symptoms in Parkinson's disease (PD) subjects suffering from delayed or unreliable onset of levodopa (L-dopa) action.
- Conditions
- Parkinson's Disease, Motor Symptoms, Akinesia, Hypomobility
- Trial name
- AM IMPAKT (NCT01770145)
- Testing
- APOKYN, L-dopa, Trimethobenzamide
- Where
- 12 sites in United States
- Volunteers
- 127 people
- Sponsor
- MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Partial Onset Seizures
A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)
This was a Non-interventional Prospective Study. Centres enrolled adult patients with partial-onset seizures with or without secondary generalisation for whom the clinician had decided to initiate Eslicarbazepine Acetate (ESL) as…
- Trial name
- NCT01830400
- Testing
- Eslicarbazepine Acetate tablets
- Where
- 106 sites in Czechia, Denmark and 6 more
- Volunteers
- 254 people
- Sponsor
- Eisai Inc.